Study of Pembrolizumab combined with Ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study

2023-509457-31-00 Phase I and Phase II (Integrated) - Other Ended

Start 1 Sep 2019 · End 1 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ended
Participants planned 47
Countries 1
Sites 1

metastatic colon cancer, advanced cancer of the colon

Key facts

Sponsor
Amsterdam UMC
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
1 Sep 2019 → 1 Dec 2025
Decision date (initial)
2024-05-13
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-509457-31-00
EudraCT number
2017-004752-34

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

metastatic colon cancer, advanced cancer of the colon

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Amsterdam UMC

Sponsor organisation
Amsterdam UMC
Address
De Boelelaan 1117
City
Amsterdam
Postcode
1081 HV
Country
Netherlands

Scientific contact point

Organisation
Amsterdam UMC
Contact name
Dr. A.D. Bins

Public contact point

Organisation
Amsterdam UMC
Contact name
Dr. A.D. Bins

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 47 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Stichting Amsterdam UMC
Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2019-09-01 2025-12-01 2019-09-13 2023-12-31

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-08 Netherlands Acceptable
2024-05-13
2024-05-13